Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

Not sure the Ph1 tox is relevant to RB other than

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
Posted On: 08/30/2013 6:39:50 PM
Posted By: BigKahuna
Re: seel #10825
Not sure the Ph1 tox is relevant to RB other than even at current mg/kg the drug appears safe for direct delivery to ocular areas. Since 2010 there have been a number of breakthroughs in ocular region drug delivery. Just wondering what you think of this article  and device (among several different new delivery methods) as it might apply to Kevetrin. Note the paragraph stating 1/100th the dose of that delivered systemically.


A Tiny Silicone Cup Improves Drug Delivery for Eye Diseases



By LYNN YOFFEE
Medical Device Daily Staff Writer

Physicians and researchers have, for years, tried to get drugs into the eyes without a great deal of success. Much of it washes away and also gets absorbed into the body's system. A tiny silicone cup sealed to the outer surface of the eye may provide a more effective method for the delivery of medicines for retinal and vitreous diseases such as cancer, macular degeneration and diabetic retinopathy.


"We can get higher levels of drug in the eye with one-one-hundredth of the dose we'd get giving it systemically," A. Linn Murphree, MD , director of the  Retinoblastoma Program in The Vision Center at Children's Hospital Los Angeles told Medical Device Daily . "So the patient would get much higher levels with lower exposures and virtually none getting into the systemic circulation."


Murphree's work centers on treating retinoblastoma, a cancer of the retina that typically afflicts children, which calls for chemotherapy. Current treatment involves intravenous delivery.


"We wanted any type of system to get chemotherapy into the eye in a better way," Murphree said. So he and two other colleagues invented silicone cup, which differs from any sort of implant or insert currently available because it's non-invasive and is attached temporarily with a bioadhesive glue.


"Think about a coffee cup with a flattened rim," Murphree said. "When you turn it upside down, it has a wide flange in contact with the eye and a bioadhesive is used on the lip."


The device can be reloaded with medication as needed.


Known as the episcleral drug reservoir, it holds the potential to fundamentally change the delivery of medications for all eye diseases, according to a report delivered by Murphree last week at the Association for Research in Vision and Ophthalmology (ARVO) Summer Eye Research Conference on Ophthalmic Drug Delivery Systems in Bethesda, Maryland, where he explained that it works like an organ-specific transdermal skin patch.


The cup isolates the medication targeted to the eye from being absorbed into the blood stream. It delivers medications to the interior of the eye over long periods of time up to months.


Drops, periocular injections and intraocular injections are currently used to deliver medications to the eye but generally for short periods of time.


This work is being backed by 3T Ophthalmics (Irvine, California), which holds the associated intellectual property license.


The episcleral drug reservoir is inserted under the thin, filmy conjunctiva, or covering of the eyeball, to the sclera the fibrous, protective outer layer of the eye. The cup administers the drug slowly by passive diffusion through the sclera, where it reaches the retina and vitreous. The device is so small the patient's vision is unlikely to be affected.


With preliminary testing complete, Murphree is currently developing a protocol for phase I/II clinical trials in humans, focused on retinoblastoma, to take place in 2010.


Murphree's first focus, retinoblastoma, requires relatively large doses to achieve a therapeutic concentration in the retina. A byproduct is that the chemo destroys the bone marrow and depresses the child's immune system, often leading to secondary infections. All of this delays an effective administration of the drug and the ability to treat the cancer.


"Our preliminary research shows that once the cup is fitted, the child should be able go home for several weeks. Because the drug is being administered directly into the eye and not systemically, chemotherapy dosage levels will be much lower and the debilitating side effects will be reduced," Murphree said.


He has tested the device in rabbits and observed they didn't seem to feel discomfort when the cup was attached, nor did they experience side effects as they would from systemically administered drugs.


The device is 8 mm to 10 mm with a reservoir that is about one-tenth of a millimeter. Liquids, tablets or gels could be loaded in the cup.


"We've shown that we can get 30 to 40 times more drug this way than if you gave the same amount as an injection," he said. "The difference is that you maintain the concentration radiant across the eye wall. Theoretically it could deliver drugs as large as Avastin and as small as antibiotics or steroids. It can stay on as long or as short a period as you want."


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895432/



(0)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us